NEW YORK, April 17 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC: SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced that it has retained the services of American Capital Ventures (ACV), a leading provider of comprehensive investor relations services to the small cap community, as an investor relations consultant.
Michael Braunold, President and Chief Executive Officer of SPO Medical commented, "As we continue to grow our revenues and enhance our distribution base, it has become increasingly important to reach out to the investment community. Our goal is to inform current and prospective investors of our financial prospects and the value proposition offered by our product pipeline and strategy." Mr. Braunold continued, "Our portable devices and new consumer applications will appeal to an ever growing number of markets globally. This is a powerful message we need to convey to investors and American Capital Ventures has a proven track record assisting small cap companies in communicating their message to the investor community."
Howard Gostfrand, President of American Capital Ventures, commented, "SPO Medical has positioned itself well in the burgeoning medical field of non-invasive devices. They have clearly laid the groundwork with key investments and strategic partnerships that have been delivering tangible results. Achieving revenues of $5 million in 2007 after only three years, and with an impressive product channel, SPOM is a perfect example of a promising undiscovered small cap company worth an investor's consideration."
About SPO Medical
SPO Medical (SPOM) is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com.
About American Capital Ventures (ACV)
American Capital Ventures (ACV) is a boutique investor relations firm founded on the principals of hard work, professionalism and integrity. Our company offers emerging growth companies a different, more comprehensive approach to investor relations. ACV delivers highly effective investor communications counsel in conjunction with developing tangible brokerage relationships for our clients. Our unique blend of creating awareness while effectively increasing a company's trading volume has allowed us to continually expand our business. Our goal is to allow management the ability to focus on their core business, while assisting them in communicating their message and develop their investor relationships.
This press release contains forward-looking statements that involve
substantial uncertainties and risks. These forward-looking statements are
based upon our current expectations, estimates and projections about our
business and our industry, and that reflect our beliefs and assumptions
based upon information available to us at the date of this release. We
caution readers that forward-looking statements are predictions based on
our current expectations about future events. These forward-looking
statements are not guarantees of future performance and are subject to
risks, uncertainties and assumptions that are difficult to predict. Our
actual results, performance or achievements could differ materially from
those expressed or implied by the forward-looking statements as a result of
a number of factors, including but not limited to, changes in economic
conditions generally and the medical devices market specifically, changes
in technology, legislative or regulatory changes that affect us, the
availability of working capital, the introduction of competing products,
market acceptance of our new products, changes in our operating strategy or
development plans and the risks and uncertainties discussed under the
heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for
the fiscal year ended December 31, 2007. We undertake no obligation to
revise or update any forward-looking statement for any reason.
SPO Medical Contact:
Michael Braunold, President & CEO,
Howard Gostfrand / David Sasso,
|SOURCE SPO Medical Inc|
Copyright©2008 PR Newswire.
All rights reserved